Aurora Urges Shareholders to Take No Action on Curaleaf's Revised US$5.00 Hostile Bid
ACB sits 79% above its 52-week low of $2.56.
Summary
Aurora Cannabis responded to Curaleaf's revised hostile bid of US$5.00 per share, urging shareholders to take no action while its Special Committee conducts a formal review. The bid deadline has been extended to at least December 4, 2026.
Updates
· SEC 6-K — Kingsdale Advisors has been appointed as Aurora Cannabis Inc.'s strategic advisor and information agent.
- Revised Bid Terms — Curaleaf filed a Notice of Variation and Change to revise its hostile take-over bid. The revised implied consideration is US$5.00 per Aurora Share, consisting of 0.4013 subordinate voting shares of Curaleaf plus US$1.00 in cash per Aurora Share.
- Advisor Contact — Kingsdale Advisors' toll-free number is 1-800-749-9052, call or text number is 416-623-4172, and email address is contactus@kingsdaleadvisors.com.
All 5 details
- Curaleaf filed a Notice of Variation and Change to revise its hostile take-over bid for all issued and outstanding common shares of Aurora Cannabis Inc.
- The revised implied consideration is US$5.00 per Aurora Share, consisting of 0.4013 subordinate voting shares of Curaleaf plus US$1.00 in cash per Aurora Share.
- Kingsdale Advisors' toll-free number is 1-800-749-9052.
- Kingsdale Advisors' call or text number is 416-623-4172.
- Kingsdale Advisors' email address is contactus@kingsdaleadvisors.com.
Key Events · M&A and Partnerships · ACB
-
Revised Hostile Bid Response
Aurora's Special Committee will commence a thorough and independent review of Curaleaf's revised hostile bid of US$5.00 per share (0.4013 Curaleaf shares plus US$1.00 cash), up from US$4.00.
-
Take No Action Advisory
Shareholders are advised to take no action pending a formal recommendation from the Board, which will be communicated via news release and Directors' Circular.
-
Extended Bid Deadline
The revised expiry date of Curaleaf's hostile bid is at least December 4, 2026, giving shareholders additional time to consider their options.
-
Prior Recommendation Stands
Aurora's board previously recommended shareholders reject the original US$4.00 bid on September 2, 2026, citing a fairness opinion valuing Aurora higher.
Analysis · ACB · Life Sciences
Aurora's board is formally reviewing Curaleaf's revised hostile bid of US$5.00 per share (0.4013 Curaleaf shares plus US$1.00 cash), up from US$4.00. The Special Committee will conduct an independent review and shareholders are advised to take no action until a formal recommendation is issued. The revised bid deadline extends to at least December 4, 2026, giving shareholders time to evaluate the offer. This is a critical juncture in the ongoing takeover battle — the board's eventual recommendation will determine whether shareholders accept a premium or hold out for a higher bid.
How filings like this one have moved
In the 30 days to Oct 7, 2026, 36.1% of the 1056 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $4.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $297.6M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.